Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 3, 1999, Pages 211-215

  Milella, M ^a   Santantonio, T ^a   Pietromatera, G ^a   Maselli, R ^a,b   Casalino, C ^a,b   Mariano, N ^a,b   Genchi, C ^a,b   Pastore, G ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b Clinica Delle Malattie Infettive   (Italy)

Author keywords

Chronic hepatitis C; Interferon; Ribavirin

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033066478     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effect of dose and duration. Hepatology 1996;24:778-89.
2. Patterson H, Fernandez-Loisson R. Molecular mechanism of action of ribavirin. Rev Infect Dis 1990;12:1139-46.
3. Reichard O, Anderson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1055-61.
4. Di Bisceglie A, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-54.
5. Reichard O, Yun ZB, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993;41:99-103.
6. Brillanti S, Garson J, Foli M, Mauro F, Whitby K, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon for alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
7. Chemello L, Cavaletto L, Bernardinello T, Silvestri E, Benvegnu L, Pontisso P, et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23:8-12.
8. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and lymphoblastoid -interferon vs -Interferon alone in the treatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepatol 1997;4:185-91.
9. Schalm S, Hansen B, Chemello L, Bellobuono A, Brouver JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patients data from European centers. J Hepatol 1997;26:961-6.
10. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-26 and ribavirin for chronic hepatitis C in patients who failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23:17-21.
11. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol 1996;28:505-11.
12. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-9.
13. Martinot-Peignoux M, Marcellin P, Poutreau M, Castelnau C, Boyer N, Pouliavin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
14. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to Interferon alfa therapy in chronic hepatitis C. Hepatology 1996;22:1326-9.
15. Davis GL, Lau JYN. Factors predictive of beneficial response to therapy of hepatitis C. Hepatology 1997;26(Suppl 1):122-7.
16. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
17. McHutchison JG, Stuart C, Gordon SC, Schiff ER, Shiffman ML, Lee WM, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 1998;339:1485-92.
18. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl J Med 1998;339:1493-9.
19. Lee J.H, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol 1998;29:29-35.
20. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: Effect of ribavirin and Interferon alfa on viral turnover. Hepatology 1998;28:245-52.
21. Milella M, Antonelli S, Santantonio T, Giannelli E, Currenti M, Monno L, et al. Treatment with natural IRN of hepatitis C patients with or without antibodies to recombinant IFN. HepatoGastroenterology 1995;42:201-4.
22. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. New Engl J Med 1997;335:347-56.